Daewoong’s patent trial for ezetimibe while the patent is expiring in 2 months

Daewoong Pharmaceutical has attracted attention as filing a patent lawsuit for ‘ezetimibe,’ a substance for the MSD’s hyperlipidemia treatment, which will be expired in 2 months.

Ezetimibe is a substance contained in the MSD’s complex drugs, Atozet and Vytorin. Atozet is a complex hyperlipidemia treatment launched by MSD on the last April after Vytorin. Since the substance patent of ezetimibe ...